Effects of a Buriti Supplement on Body Composition and Function in Older Adults
31. August 2026 aktualisiert von: Sergio Henrique Sousa Santos, Federal University of Minas Gerais
Effects of "Nutricer®" Vegan Protein Supplementation Based on Buriti (Mauritia Flexuosa), Rice, and Pea on Body Composition, Flexibility, Balance, and Dietary Frequency in Elderly Tai Chi Chuan Practitioners: A Placebo-Controlled Clinical Trial
Aging is a natural process commonly associated with loss of muscle mass, reduced flexibility, and impaired balance, directly affecting the quality of life of older adults.
Tai Chi Chuan, a traditional mind-body practice, has been shown to improve balance, flexibility, and overall well-being in elderly populations.
In addition, nutritional supplementation may enhance these effects, particularly when based on plant-derived functional compounds.This study aims to evaluate the effects of vegan protein supplementation with Nutricer®-based on buriti (Mauritia flexuosa), rice, and pea-on body composition, muscle strength, flexibility, balance, and dietary frequency in elderly women practicing Tai Chi Chuan.
This is a placebo-controlled clinical trial involving 40 elderly female participants, randomly assigned into two groups: an experimental group (n = 20), receiving Nutricer® supplementation, and a control group (n = 20), receiving a placebo (maltodextrin), both alongside regular Tai Chi Chuan practice.Buriti is known for its antioxidant and anti-inflammatory properties, which may contribute to the preservation of muscle and functional health.
It is expected that the combination of vegan protein supplementation and Tai Chi Chuan practice will result in significant improvements in functional health, providing a natural, accessible, and safe strategy for healthy aging.
Studienübersicht
Status
Abgeschlossen
Bedingungen
Studientyp
Interventionell
Einschreibung (Tatsächlich)
40
Phase
- Unzutreffend
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
Minas Gerais
-
Montes Claros, Minas Gerais, Brasilien, 39401002
- State University of Minas Gerais
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Ja
Beschreibung
Inclusion Criteria:
- Female participants aged 60 years or older
- Participation in a Tai Chi Chuan program (at least twice per week, 60-minute sessions)
- Commitment to remain in the study throughout the intervention period (e.g., 12 weeks)
- Ability to understand and respond to questionnaires and perform the proposed physical tests
- Willingness to participate and provide written informed consent (Informed Consent Form)
Exclusion Criteria:
• Current use of protein supplements, vitamins, or similar products to the study supplement
- Medical contraindications to performing light to moderate physical exercise
- Diseases or conditions that significantly impair mobility (e.g., severe stroke sequelae, advanced Parkinson's disease)
- Moderate to severe cognitive impairment (e.g., dementia)
- Irregular participation in Tai Chi Chuan sessions (absence greater than 20% during the intervention period)
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Experimental Group
Participants will receive vegan protein supplementation with Nutricer® (based on buriti, rice, and pea), in addition to regular Tai Chi Chuan practice.
|
Vegan protein supplement based on buriti (Mauritia flexuosa), rice and pea.
Participants will participate in a supervised Tai Chi Chuan program consisting of structured sessions led by a qualified instructor throughout the intervention period.
|
|
Placebo-Komparator: Placebo Comparator
Participants will receive a placebo (maltodextrin), in addition to regular Tai Chi Chuan practice
|
Participants will participate in a supervised Tai Chi Chuan program consisting of structured sessions led by a qualified instructor throughout the intervention period.
Placebo supplement (maltodextrin), administered daily during the study period.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Body weight (kg)
Zeitfenster: Baseline and week 12.
|
Body weight will be measured using a calibrated digital scale and recorded in kilograms (kg).
|
Baseline and week 12.
|
|
Lean body mass percentage (%)
Zeitfenster: Baseline and week 12
|
Lean body mass percentage will be assessed using bioelectrical impedance analysis (BIA) and expressed as a percentage of total body mass.
|
Baseline and week 12
|
|
Body fat percentage (%)
Zeitfenster: Baseline and week 12.
|
Body fat percentage will be assessed using bioelectrical impedance analysis (BIA) and expressed as a percentage of total body mass.
|
Baseline and week 12.
|
|
Handgrip strength (kg)
Zeitfenster: Baseline and week 12
|
Assessment of muscle strength using handgrip strength test with a digital dynamometer and recorded in kilograms (kg).
|
Baseline and week 12
|
|
Plasma glucose concentration (mg/dL)
Zeitfenster: Baseline and Week 12
|
Plasma glucose concentration (mg/dL) will be measured using an enzymatic colorimetric assay.
|
Baseline and Week 12
|
|
Percentage of plasma glycosylated hemoglobin (HbA1c) (%)
Zeitfenster: Baseline and Week 12
|
Glycosylated hemoglobin (HbA1c) (%) will be measured in whole blood.
|
Baseline and Week 12
|
|
Plasma LDL cholesterol concentration (mg/dL)
Zeitfenster: Baseline and week 12
|
Plasma low-density lipoprotein (LDL) cholesterol concentration (mg/dL) will be measured using an enzymatic colorimetric assay.
|
Baseline and week 12
|
|
Plasma HDL cholesterol concentration (mg/dL)
Zeitfenster: Baseline and week 12
|
Plasma high-density lipoprotein (HDL) cholesterol concentration (mg/dL) will be measured using an enzymatic colorimetric assay.
|
Baseline and week 12
|
|
Plasma total cholesterol concentration (mg/dL)
Zeitfenster: Baseline and Week 12
|
Plasma total cholesterol concentration (mg/dL) will be measured using an enzymatic colorimetric assay.
|
Baseline and Week 12
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Functional balance assessed by the Timed Up and Go (TUG) test
Zeitfenster: Baseline and week 12
|
Functional balance will be assessed using the Timed Up and Go (TUG) test.
Participants will be instructed to stand up from a chair, walk 3 meters, turn around, walk back, and sit down.
The time required to complete the test will be recorded in seconds, with lower times indicating better functional mobility and balance performance.
|
Baseline and week 12
|
|
Flexibility assessed by the Sit-and-Reach test
Zeitfenster: Baseline and week 12
|
Flexibility will be assessed using the sit-and-reach test.
Participants will perform the test according to standardized procedures, and the maximum distance reached will be recorded in centimeters.
Higher values indicate greater flexibility.
|
Baseline and week 12
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Ermittler
- Hauptermittler: Sérgio H Santos, PhD, Federal University of Minas Gerais
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Tatsächlich)
1. August 2025
Primärer Abschluss (Tatsächlich)
1. Januar 2026
Studienabschluss (Tatsächlich)
1. Juni 2026
Studienanmeldedaten
Zuerst eingereicht
16. Juli 2026
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
16. Juli 2026
Zuerst gepostet (Tatsächlich)
21. Juli 2026
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
2. September 2026
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
31. August 2026
Zuletzt verifiziert
1. Juli 2026
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 7.662.055
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .